Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
321-340 of 1,307 trials

UDCA for Visual Recovery After Retinal Detachment Surgery

We are studying whether UDCA can improve vision recovery in patients who have had surgery for retinal detachment. The trial also looks at the treatment's safety and other effectiveness measures.

Rhegmatogenous Retinal Detachment≤3 monthsConfirmation phase (III)Standard MedicinesOphthalmology

Tocilizumab for Acute Chest Syndrome in Sickle Cell Disease

We are studying whether tocilizumab can help patients with sickle cell disease recover from acute chest syndrome faster and safely. The trial includes both children and adults to assess its effectiveness and safety.

Sickle Cell Disease>2 yearsConfirmation phase (III)Standard MedicinesHematologyPulmonology

Uveitis Treatment: Adalimumab vs. Mycophenolate Mofetil

We are studying whether adalimumab can improve outcomes for people with steroid-dependent non-infectious uveitis compared to the standard treatment. This trial will help us understand the effectiveness and safety of both medications.

Uveitis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

IVF Luteal Phase Support: GnRH Agonist vs. hCG

We are studying whether a GnRH agonist can improve live birth rates and reduce miscarriages in women undergoing IVF compared to traditional hCG and progesterone support.

Assisted Reproductive Technology≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesGynecology and Obstetrics

Childhood Onset Nephrotic Syndrome: Obinutuzumab vs. MMF

We are studying whether obinutuzumab is more effective and safer than MMF for children with childhood onset idiopathic nephrotic syndrome. We will also look at how these treatments affect fatigue and quality of life.

Childhood Idiopathic Nephrotic Syndrome1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Efruxifermin for Non-Cirrhotic NASH/MASH

We are studying whether Efruxifermin can improve liver health and reduce fibrosis in people with Non-Cirrhotic NASH or MASH. Participants will be compared to those receiving a placebo to assess safety and effectiveness.

Non-alcoholic Fatty Liver DiseaseHepatic Fibrosis1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesEndocrinologyHepatology

Colon Cancer Treatment: Neo-Adjuvant Chemotherapy for Seniors

We are studying whether a 6-week chemotherapy treatment before surgery helps older adults with resectable colon cancer live longer and stay disease-free. This trial aims to personalize treatment for patients aged 70 and older.

Colon Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Acute Pancreatitis: Omega-3 Fatty Acid Infusion

We are studying whether early intravenous omega-3 fatty acids can help reduce organ failure and mortality in patients with acute pancreatitis. This trial compares the effects of omega-3s to standard medical care.

Severe Acute Pancreatitis6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesGastroenterologyInternal Medicine

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia

We are comparing a new treatment, bomedemstat, to hydroxyurea in people with essential thrombocythemia who haven't been treated before. The goal is to see which treatment better reduces symptoms and fatigue.

Essential Thrombocythemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteHematology

Autism Spectrum Disorder: Sensorimotor Therapy and Oxytocin

We are exploring whether a new therapy combined with a single dose of oxytocin can improve social connections in children with autism. The goal is to see if this approach enhances their interactions with others.

Autism Spectrum Disorder>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPsychiatry

High-Risk Retroperitoneal Sarcoma: Chemotherapy Before Surgery

We are testing whether chemotherapy before surgery improves outcomes for patients with high-risk retroperitoneal sarcoma. This study compares the effects of preoperative chemotherapy to surgery alone.

Dedifferentiated LiposarcomaLeiomyosarcoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Glioblastoma Treatment: Lomustine with or without Reirradiation

We are studying whether adding a second round of radiation to lomustine improves survival and quality of life for patients with recurrent glioblastoma. This trial aims to find out if this combination is more effective than lomustine alone.

Glioblastoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Treatment-Resistant Depression: COMP360 Study

We are studying whether two doses of COMP360 can improve symptoms in adults with treatment-resistant depression. This trial includes psychological support to enhance treatment effects.

Major Depressive DisorderTreatment-Resistant Depression6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Coronary Disease: Tirzepatide Study

We are exploring whether tirzepatide can improve heart health by changing plaque composition and blood flow in people with obesity and coronary artery disease. This study compares tirzepatide to a placebo to assess its effects.

Overweight and Obesity1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Diffuse Large B-Cell Lymphoma: Epcoritamab with R-CHOP

We are studying whether adding Epcoritamab to standard R-CHOP treatment helps people with newly diagnosed Diffuse Large B-Cell Lymphoma live longer without disease progression. This trial compares the new combination to R-CHOP alone.

Diffuse Large B-Cell Lymphoma1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Melanoma: IMC-F106C Plus Nivolumab

We are studying a new treatment combination for people with previously untreated advanced melanoma. The goal is to see if it helps patients live longer and have better outcomes compared to standard treatment.

Advanced Melanoma1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyOncology

Metastatic Non-Small Cell Lung Cancer: ONC-392 vs. Docetaxel

We are studying a new treatment, ONC-392, to see if it helps patients with metastatic non-small cell lung cancer who have progressed on immunotherapy. The goal is to compare its effectiveness and safety against the standard treatment, docetaxel.

Metastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Brain Injury: Effects of Ketamine Treatment

We are studying whether adding ketamine to treatment helps lower the intensity of care needed for patients with acute brain injuries. We also want to see if it affects intracranial pressure.

Traumatic Brain Injury>2 yearsConfirmation phase (III)Monitoring phase (IV)Standard MedicinesNeurologyOtolaryngology

Hidradenitis Suppurativa: Bimekizumab for Teens

We are studying how the drug bimekizumab works and its safety for treating moderate to severe hidradenitis suppurativa in pubertal children and adolescents.

Hidradenitis SuppurativaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesAllergologyDermatology

Influenza Vaccine Study for Hematological Cancer Patients

We are testing whether a high-dose flu vaccine works better than a standard dose in patients with hematological cancers. This study aims to improve vaccine effectiveness and understand immune responses in these patients.

Hematological Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyInfectious Diseases